Consultant

• Oct 2023 - Present

Director of Clinical Toxicology and Pharmacology

• May 2022 - Oct 2023

𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐮𝐩 𝐭𝐡𝐞 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐨𝐱𝐢𝐜𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐲 𝐩𝐫𝐨𝐠𝐫𝐚𝐦: I validated LC-MS/MS methods for testing 78 drugs in urine for clinical toxicology. I developed LC-MS/MS method for detecting Bradykinin 1-9 and its metabolites in blood for clinical pharmacology. 𝐂𝐞𝐫𝐭𝐚𝐫𝐚 𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐞𝐝 𝐍𝐂𝐀 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐚𝐧𝐝 𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐏𝐊/𝐏𝐃 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐦𝐞𝐭𝐫𝐢𝐜𝐢𝐚𝐧 𝐚𝐧𝐝 𝐒𝐤𝐢𝐥𝐥𝐞𝐝 𝐢𝐧 𝐍𝐎𝐍𝐌𝐄𝐌… Show more 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐮𝐩 𝐭𝐡𝐞 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐨𝐱𝐢𝐜𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐲 𝐩𝐫𝐨𝐠𝐫𝐚𝐦: I validated LC-MS/MS methods for testing 78 drugs in urine for clinical toxicology. I developed LC-MS/MS method for detecting Bradykinin 1-9 and its metabolites in blood for clinical pharmacology. 𝐂𝐞𝐫𝐭𝐚𝐫𝐚 𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐞𝐝 𝐍𝐂𝐀 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐚𝐧𝐝 𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐏𝐊/𝐏𝐃 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐦𝐞𝐭𝐫𝐢𝐜𝐢𝐚𝐧 𝐚𝐧𝐝 𝐒𝐤𝐢𝐥𝐥𝐞𝐝 𝐢𝐧 𝐍𝐎𝐍𝐌𝐄𝐌, 𝐖𝐢𝐧𝐍𝐨𝐧𝐥𝐢𝐧 𝐚𝐧𝐝 𝐍𝐋𝐌𝐄: I possess a deep understanding of PK/PD theory and extensive expertise in NCA analysis, individual and population PK/PD modeling & simulation. Below is a representative list of my capabilities for NCA analysis, PK/PD modeling & simulation: 𝘕𝘖𝘕𝘔𝘌𝘔 𝘚𝘬𝘪𝘭𝘭𝘴 1) Defining preliminary structural and random effect models. 2) Coding the structural model and random error models, including 1- and 2-compartmental models. 3) Optimizing individual PK models. 4) Model evaluation: • Goodness of Fit Diagnostics. • Diagnostic plots. • Likelihood ratio test. • Akaike Information Criterion (AIC). • Schwarz Bayesian Criterion (SBC). 5) Developing full population PK models with covariates (continuous and categorical variables). • Forward addition. • Backward elimination. 6) Performing model validation: • Bootstrap. • Visual Predictive Check. 7) Utilizing user-written PK-PD models: • Direct PK-PD models. • Indirect PK-PD models. 𝘗𝘩𝘰𝘦𝘯𝘪𝘹 𝘞𝘪𝘯𝘕𝘰𝘯𝘭𝘪𝘯 𝘢𝘯𝘥 𝘕𝘓𝘔𝘌 𝘚𝘬𝘪𝘭𝘭𝘴 1) Conducting non-compartmental analysis (NCA). 2) Creating individual and population PK models. 3) Performing model-based simulations and predictions. 4) Conducting model evaluation using diagnostic plots and goodness of fit assessments. 5) Building and fitting nonlinear mixed effects models. 6) Estimating population pharmacokinetic parameters. 7) Incorporating inter-individual and residual variability in the models. 8) Performing model diagnostics and evaluation.

Senior Director of Pharmacology, Toxicology and Radiopharmaceutical Development

• Oct 2023 - Present

PET Radiochemist

• Jun 2017 - May 2022

𝘗𝘌𝘛 𝘙𝘢𝘥𝘪𝘰𝘵𝘳𝘢𝘤𝘦𝘳 𝘊𝘦𝘯𝘵𝘦𝘳 𝘪𝘯 𝘑𝘰𝘩𝘯𝘴 𝘏𝘰𝘱𝘬𝘪𝘯𝘴 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘪𝘴 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘳𝘦𝘮𝘪𝘦𝘳 𝘤𝘦𝘯𝘵𝘦𝘳𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘰𝘧 𝘯𝘦𝘸 𝘳𝘢𝘥𝘪𝘰𝘢𝘤𝘵𝘪𝘷𝘦 𝘥𝘳𝘶𝘨𝘴, 𝘢𝘯𝘥 𝘧𝘰𝘳 𝘮𝘢𝘯𝘢𝘨𝘪𝘯𝘨 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘰𝘶𝘳 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺. 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐭 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭 𝐢𝐧 𝐜𝐆𝐌𝐏 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬… Show more 𝘗𝘌𝘛 𝘙𝘢𝘥𝘪𝘰𝘵𝘳𝘢𝘤𝘦𝘳 𝘊𝘦𝘯𝘵𝘦𝘳 𝘪𝘯 𝘑𝘰𝘩𝘯𝘴 𝘏𝘰𝘱𝘬𝘪𝘯𝘴 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘪𝘴 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘳𝘦𝘮𝘪𝘦𝘳 𝘤𝘦𝘯𝘵𝘦𝘳𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘰𝘧 𝘯𝘦𝘸 𝘳𝘢𝘥𝘪𝘰𝘢𝘤𝘵𝘪𝘷𝘦 𝘥𝘳𝘶𝘨𝘴, 𝘢𝘯𝘥 𝘧𝘰𝘳 𝘮𝘢𝘯𝘢𝘨𝘪𝘯𝘨 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘰𝘶𝘳 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺. 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐭 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭 𝐢𝐧 𝐜𝐆𝐌𝐏 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐟𝐨𝐫 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: PET Radiotracer Center in Johns Hopkins University Hospital is a well-established cGMP pharmaceutical manufacturing facility. I gained expertise in manufacturing and quality control of radiopharmaceuticals in cGMP facility according to the regulations and guidelines set by 21 CFR 212, USP 32 <823>, and USP 39 <823>. The radiopharmaceuticals investigated at this stage represent the best candidates to be most likely approved for routine clinical use. My cGMP experience offers me hands-on expertise in understanding the FDA regulations of finished drugs including product controls, formulation, QC acceptance criteria, packaging, labeling, distribution, complaint handling, and recording. Most of radiopharmaceuticals that I am currently working on are used in clinical research for neuroimaging, which are [11C]-CAR (for Mu-opioid receptor), [11C]-DASB (for serotonin transporter/clinical research), [11C]-DPA (for translocator protein (TSPO)/phase 1 clinical trial), [11C]-LUC (for serotonin receptor/clinical research), [11C]-OMAR (for cannabinoid receptors/phase 1 clinical trial), [11C]-PIB (for aβ plaques/phase 1 clinical trial), [11C]-RAC (for D2-Dopamine receptor/clinical research), [11C]-RIF (for pregnane X receptor/clinical research), [11C]-NNA (for D1-Dopamine receptor/clinical research). I have produced more than 1000 doses of radiopharmaceuticals that have been successfully administered to human beings. Show less 𝘗𝘌𝘛 𝘙𝘢𝘥𝘪𝘰𝘵𝘳𝘢𝘤𝘦𝘳 𝘊𝘦𝘯𝘵𝘦𝘳 𝘪𝘯 𝘑𝘰𝘩𝘯𝘴 𝘏𝘰𝘱𝘬𝘪𝘯𝘴 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘪𝘴 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘳𝘦𝘮𝘪𝘦𝘳 𝘤𝘦𝘯𝘵𝘦𝘳𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘰𝘧 𝘯𝘦𝘸 𝘳𝘢𝘥𝘪𝘰𝘢𝘤𝘵𝘪𝘷𝘦 𝘥𝘳𝘶𝘨𝘴, 𝘢𝘯𝘥 𝘧𝘰𝘳 𝘮𝘢𝘯𝘢𝘨𝘪𝘯𝘨 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘰𝘶𝘳 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺. 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐭 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭 𝐢𝐧 𝐜𝐆𝐌𝐏 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬… Show more 𝘗𝘌𝘛 𝘙𝘢𝘥𝘪𝘰𝘵𝘳𝘢𝘤𝘦𝘳 𝘊𝘦𝘯𝘵𝘦𝘳 𝘪𝘯 𝘑𝘰𝘩𝘯𝘴 𝘏𝘰𝘱𝘬𝘪𝘯𝘴 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘪𝘴 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘳𝘦𝘮𝘪𝘦𝘳 𝘤𝘦𝘯𝘵𝘦𝘳𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘸𝘰𝘳𝘭𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘰𝘧 𝘯𝘦𝘸 𝘳𝘢𝘥𝘪𝘰𝘢𝘤𝘵𝘪𝘷𝘦 𝘥𝘳𝘶𝘨𝘴, 𝘢𝘯𝘥 𝘧𝘰𝘳 𝘮𝘢𝘯𝘢𝘨𝘪𝘯𝘨 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘪𝘯 𝘰𝘶𝘳 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺. 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐭 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭 𝐢𝐧 𝐜𝐆𝐌𝐏 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐟𝐨𝐫 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: PET Radiotracer Center in Johns Hopkins University Hospital is a well-established cGMP pharmaceutical manufacturing facility. I gained expertise in manufacturing and quality control of radiopharmaceuticals in cGMP facility according to the regulations and guidelines set by 21 CFR 212, USP 32 <823>, and USP 39 <823>. The radiopharmaceuticals investigated at this stage represent the best candidates to be most likely approved for routine clinical use. My cGMP experience offers me hands-on expertise in understanding the FDA regulations of finished drugs including product controls, formulation, QC acceptance criteria, packaging, labeling, distribution, complaint handling, and recording. Most of radiopharmaceuticals that I am currently working on are used in clinical research for neuroimaging, which are [11C]-CAR (for Mu-opioid receptor), [11C]-DASB (for serotonin transporter/clinical research), [11C]-DPA (for translocator protein (TSPO)/phase 1 clinical trial), [11C]-LUC (for serotonin receptor/clinical research), [11C]-OMAR (for cannabinoid receptors/phase 1 clinical trial), [11C]-PIB (for aβ plaques/phase 1 clinical trial), [11C]-RAC (for D2-Dopamine receptor/clinical research), [11C]-RIF (for pregnane X receptor/clinical research), [11C]-NNA (for D1-Dopamine receptor/clinical research). I have produced more than 1000 doses of radiopharmaceuticals that have been successfully administered to human beings. Show less

Research Associate

• Jun 2017 - May 2022

𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐍𝐞𝐰 𝐑𝐚𝐝𝐢𝐨𝐚𝐜𝐭𝐢𝐯𝐞 𝐃𝐫𝐮𝐠𝐬 𝐟𝐨𝐫 𝐈𝐍𝐃 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐓𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: I played an important role in assisting the team in developing a CSF1R-targeted preclinical drug candidate called CPPC for neuroimaging. This involved translating [11C]-CPPC into a phase 1 clinical trial, as evidenced by publications in the National Academy of Sciences USA (2019, 116(5), 1686-169) and the Journal of Labelled… Show more 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐍𝐞𝐰 𝐑𝐚𝐝𝐢𝐨𝐚𝐜𝐭𝐢𝐯𝐞 𝐃𝐫𝐮𝐠𝐬 𝐟𝐨𝐫 𝐈𝐍𝐃 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐓𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: I played an important role in assisting the team in developing a CSF1R-targeted preclinical drug candidate called CPPC for neuroimaging. This involved translating [11C]-CPPC into a phase 1 clinical trial, as evidenced by publications in the National Academy of Sciences USA (2019, 116(5), 1686-169) and the Journal of Labelled Compounds and Radiopharmaceuticals (2019, 62(13), 903-908), as well as a clinical trial registration at https://clinicaltrials.gov/ct2/show/NCT04749433. Additionally, I helped to translate [11C]-MDTC (published in the Journal of Nuclear Medicine, 2019, 60 (Supplement_1), 326, and submitted for publication in the European Journal of Nuclear Medicine and Molecular Imaging in 2022) and [11C]-DPA (published in EJNMMI Research, 2022, 12(1):64) into first-in-human studies. Working in collaboration with Roche, a global pioneer company in pharmaceuticals and diagnostics, I played an important role in translating new preclinical drug precursors into new radiopharmaceuticals. These included [11C]-RO3605, -RO1356, -RO5378, -RO4524, -R-Ketamine, and -S-Ketamine. I also helped to develop translation protocols in our cGMP pharmaceutical facility and prepared experimental data for IND or Radioactive Drug Research Committee (RDRC) applications. All the new preclinical drugs were investigated in baboons to evaluate their biodistribution and pharmacokinetic properties in the brain. [11C]-CPPC (for CSF1R), -MDTC (for cannabinoid receptor), and -RO5378 (for GABAA receptor) were successfully translated into first-in-human studies. Show less 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐍𝐞𝐰 𝐑𝐚𝐝𝐢𝐨𝐚𝐜𝐭𝐢𝐯𝐞 𝐃𝐫𝐮𝐠𝐬 𝐟𝐨𝐫 𝐈𝐍𝐃 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐓𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: I played an important role in assisting the team in developing a CSF1R-targeted preclinical drug candidate called CPPC for neuroimaging. This involved translating [11C]-CPPC into a phase 1 clinical trial, as evidenced by publications in the National Academy of Sciences USA (2019, 116(5), 1686-169) and the Journal of Labelled… Show more 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐍𝐞𝐰 𝐑𝐚𝐝𝐢𝐨𝐚𝐜𝐭𝐢𝐯𝐞 𝐃𝐫𝐮𝐠𝐬 𝐟𝐨𝐫 𝐈𝐍𝐃 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐓𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: I played an important role in assisting the team in developing a CSF1R-targeted preclinical drug candidate called CPPC for neuroimaging. This involved translating [11C]-CPPC into a phase 1 clinical trial, as evidenced by publications in the National Academy of Sciences USA (2019, 116(5), 1686-169) and the Journal of Labelled Compounds and Radiopharmaceuticals (2019, 62(13), 903-908), as well as a clinical trial registration at https://clinicaltrials.gov/ct2/show/NCT04749433. Additionally, I helped to translate [11C]-MDTC (published in the Journal of Nuclear Medicine, 2019, 60 (Supplement_1), 326, and submitted for publication in the European Journal of Nuclear Medicine and Molecular Imaging in 2022) and [11C]-DPA (published in EJNMMI Research, 2022, 12(1):64) into first-in-human studies. Working in collaboration with Roche, a global pioneer company in pharmaceuticals and diagnostics, I played an important role in translating new preclinical drug precursors into new radiopharmaceuticals. These included [11C]-RO3605, -RO1356, -RO5378, -RO4524, -R-Ketamine, and -S-Ketamine. I also helped to develop translation protocols in our cGMP pharmaceutical facility and prepared experimental data for IND or Radioactive Drug Research Committee (RDRC) applications. All the new preclinical drugs were investigated in baboons to evaluate their biodistribution and pharmacokinetic properties in the brain. [11C]-CPPC (for CSF1R), -MDTC (for cannabinoid receptor), and -RO5378 (for GABAA receptor) were successfully translated into first-in-human studies. Show less

Senior Research Scientist

• Oct 2016 - Jun 2017

𝘛𝘩𝘦 𝘊𝘺𝘤𝘭𝘰𝘵𝘳𝘰𝘯 𝘢𝘯𝘥 𝘙𝘢𝘥𝘪𝘰𝘤𝘩𝘦𝘮𝘪𝘴𝘵𝘳𝘺 𝘗𝘳𝘰𝘨𝘳𝘢𝘮 𝘢𝘵 𝘜𝘛 𝘚𝘰𝘶𝘵𝘩𝘸𝘦𝘴𝘵𝘦𝘳𝘯 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘊𝘦𝘯𝘵𝘦𝘳 𝘸𝘢𝘴 𝘦𝘴𝘵𝘢𝘣𝘭𝘪𝘴𝘩𝘦𝘥 𝘶𝘯𝘥𝘦𝘳 𝘵𝘩𝘦 𝘢𝘶𝘴𝘱𝘪𝘤𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘊𝘢𝘯𝘤𝘦𝘳 𝘗𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘐𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘰𝘧 𝘛𝘦𝘹𝘢𝘴 (𝘊𝘗𝘙𝘐𝘛) 𝘪𝘯 2015 𝘵𝘰 𝘭𝘦𝘷𝘦𝘳𝘢𝘨𝘦 𝘵𝘩𝘦 𝘤𝘶𝘵𝘵𝘪𝘯𝘨-𝘦𝘥𝘨𝘦 𝘪𝘮𝘢𝘨𝘪𝘯𝘨 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘰𝘧 𝘗𝘌𝘛 𝘧𝘰𝘳 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭… Show more 𝘛𝘩𝘦 𝘊𝘺𝘤𝘭𝘰𝘵𝘳𝘰𝘯 𝘢𝘯𝘥 𝘙𝘢𝘥𝘪𝘰𝘤𝘩𝘦𝘮𝘪𝘴𝘵𝘳𝘺 𝘗𝘳𝘰𝘨𝘳𝘢𝘮 𝘢𝘵 𝘜𝘛 𝘚𝘰𝘶𝘵𝘩𝘸𝘦𝘴𝘵𝘦𝘳𝘯 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘊𝘦𝘯𝘵𝘦𝘳 𝘸𝘢𝘴 𝘦𝘴𝘵𝘢𝘣𝘭𝘪𝘴𝘩𝘦𝘥 𝘶𝘯𝘥𝘦𝘳 𝘵𝘩𝘦 𝘢𝘶𝘴𝘱𝘪𝘤𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘊𝘢𝘯𝘤𝘦𝘳 𝘗𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘐𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘰𝘧 𝘛𝘦𝘹𝘢𝘴 (𝘊𝘗𝘙𝘐𝘛) 𝘪𝘯 2015 𝘵𝘰 𝘭𝘦𝘷𝘦𝘳𝘢𝘨𝘦 𝘵𝘩𝘦 𝘤𝘶𝘵𝘵𝘪𝘯𝘨-𝘦𝘥𝘨𝘦 𝘪𝘮𝘢𝘨𝘪𝘯𝘨 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘰𝘧 𝘗𝘌𝘛 𝘧𝘰𝘳 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩. 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: I have successfully developed preclinical drugs that provide theranostic capacity for prostate cancer (J. Nucl. Med. 2017, 58 (Supplement_1), 1020; Cancer Res. 2018, 78 (Supplement_16), B066). The unique feature of using these new preclinical drugs for therapy is the therapeutic outcome could be noninvasively and quantitatively monitored via PET imaging. In vitro toxicity assays were tested on PSMA-positive and PSMA-negative cells. In vivo toxicity testing of drugs showed controllable acute toxicity in mice with the body weight loss all within 15%. Therapeutic results showed average tumor sizes of both high- and low-dose treatment groups stopped increasing by Day 7 and then shrinking over the course of the treatment. Biodistribution and pharmacokinetic studies of new theranostic drugs were investigated in mice. 𝐎𝐭𝐡𝐞𝐫 𝐃𝐮𝐭𝐢𝐞𝐬: assisting in the production of 64Cu and 89Zr radiometals using GE PETtrace 880 cyclotron and assisting in quality control of radiopharmaceuticals for PET imaging in clinic. Show less 𝘛𝘩𝘦 𝘊𝘺𝘤𝘭𝘰𝘵𝘳𝘰𝘯 𝘢𝘯𝘥 𝘙𝘢𝘥𝘪𝘰𝘤𝘩𝘦𝘮𝘪𝘴𝘵𝘳𝘺 𝘗𝘳𝘰𝘨𝘳𝘢𝘮 𝘢𝘵 𝘜𝘛 𝘚𝘰𝘶𝘵𝘩𝘸𝘦𝘴𝘵𝘦𝘳𝘯 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘊𝘦𝘯𝘵𝘦𝘳 𝘸𝘢𝘴 𝘦𝘴𝘵𝘢𝘣𝘭𝘪𝘴𝘩𝘦𝘥 𝘶𝘯𝘥𝘦𝘳 𝘵𝘩𝘦 𝘢𝘶𝘴𝘱𝘪𝘤𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘊𝘢𝘯𝘤𝘦𝘳 𝘗𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘐𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘰𝘧 𝘛𝘦𝘹𝘢𝘴 (𝘊𝘗𝘙𝘐𝘛) 𝘪𝘯 2015 𝘵𝘰 𝘭𝘦𝘷𝘦𝘳𝘢𝘨𝘦 𝘵𝘩𝘦 𝘤𝘶𝘵𝘵𝘪𝘯𝘨-𝘦𝘥𝘨𝘦 𝘪𝘮𝘢𝘨𝘪𝘯𝘨 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘰𝘧 𝘗𝘌𝘛 𝘧𝘰𝘳 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭… Show more 𝘛𝘩𝘦 𝘊𝘺𝘤𝘭𝘰𝘵𝘳𝘰𝘯 𝘢𝘯𝘥 𝘙𝘢𝘥𝘪𝘰𝘤𝘩𝘦𝘮𝘪𝘴𝘵𝘳𝘺 𝘗𝘳𝘰𝘨𝘳𝘢𝘮 𝘢𝘵 𝘜𝘛 𝘚𝘰𝘶𝘵𝘩𝘸𝘦𝘴𝘵𝘦𝘳𝘯 𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘊𝘦𝘯𝘵𝘦𝘳 𝘸𝘢𝘴 𝘦𝘴𝘵𝘢𝘣𝘭𝘪𝘴𝘩𝘦𝘥 𝘶𝘯𝘥𝘦𝘳 𝘵𝘩𝘦 𝘢𝘶𝘴𝘱𝘪𝘤𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘊𝘢𝘯𝘤𝘦𝘳 𝘗𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘐𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘰𝘧 𝘛𝘦𝘹𝘢𝘴 (𝘊𝘗𝘙𝘐𝘛) 𝘪𝘯 2015 𝘵𝘰 𝘭𝘦𝘷𝘦𝘳𝘢𝘨𝘦 𝘵𝘩𝘦 𝘤𝘶𝘵𝘵𝘪𝘯𝘨-𝘦𝘥𝘨𝘦 𝘪𝘮𝘢𝘨𝘪𝘯𝘨 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘰𝘧 𝘗𝘌𝘛 𝘧𝘰𝘳 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩. 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: I have successfully developed preclinical drugs that provide theranostic capacity for prostate cancer (J. Nucl. Med. 2017, 58 (Supplement_1), 1020; Cancer Res. 2018, 78 (Supplement_16), B066). The unique feature of using these new preclinical drugs for therapy is the therapeutic outcome could be noninvasively and quantitatively monitored via PET imaging. In vitro toxicity assays were tested on PSMA-positive and PSMA-negative cells. In vivo toxicity testing of drugs showed controllable acute toxicity in mice with the body weight loss all within 15%. Therapeutic results showed average tumor sizes of both high- and low-dose treatment groups stopped increasing by Day 7 and then shrinking over the course of the treatment. Biodistribution and pharmacokinetic studies of new theranostic drugs were investigated in mice. 𝐎𝐭𝐡𝐞𝐫 𝐃𝐮𝐭𝐢𝐞𝐬: assisting in the production of 64Cu and 89Zr radiometals using GE PETtrace 880 cyclotron and assisting in quality control of radiopharmaceuticals for PET imaging in clinic. Show less

Assistant Professor

• Apr 2015 - Sep 2016

𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘐𝘮𝘢𝘨𝘪𝘯𝘨 𝘓𝘢𝘣𝘰𝘳𝘢𝘵𝘰𝘳𝘺 𝘪𝘯 𝘏𝘰𝘸𝘢𝘳𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘪𝘴 𝘢 𝘴𝘺𝘯𝘦𝘳𝘨𝘪𝘴𝘵𝘪𝘤 𝘤𝘦𝘯𝘵𝘦𝘳 𝘧𝘰𝘳 𝘱𝘳𝘰𝘮𝘰𝘵𝘪𝘯𝘨 𝘮𝘶𝘭𝘵𝘪𝘥𝘪𝘴𝘤𝘪𝘱𝘭𝘪𝘯𝘢𝘳𝘺 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘧𝘰𝘳 𝘏𝘰𝘸𝘢𝘳𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘢𝘯𝘥 𝘯𝘦𝘪𝘨𝘩𝘣𝘰𝘳𝘪𝘯𝘨 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘪𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘪𝘰𝘯𝘴 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘊𝘩𝘪𝘭𝘥𝘳𝘦𝘯’𝘴 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭, 𝘎𝘦𝘰𝘳𝘨𝘦𝘵𝘰𝘸𝘯, 𝘜𝘚𝘋𝘈, 𝘝𝘈, 𝘢𝘯𝘥 𝘭𝘰𝘤𝘢𝘭 𝘣𝘪𝘰𝘵𝘦𝘤𝘩 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴… Show more 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘐𝘮𝘢𝘨𝘪𝘯𝘨 𝘓𝘢𝘣𝘰𝘳𝘢𝘵𝘰𝘳𝘺 𝘪𝘯 𝘏𝘰𝘸𝘢𝘳𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘪𝘴 𝘢 𝘴𝘺𝘯𝘦𝘳𝘨𝘪𝘴𝘵𝘪𝘤 𝘤𝘦𝘯𝘵𝘦𝘳 𝘧𝘰𝘳 𝘱𝘳𝘰𝘮𝘰𝘵𝘪𝘯𝘨 𝘮𝘶𝘭𝘵𝘪𝘥𝘪𝘴𝘤𝘪𝘱𝘭𝘪𝘯𝘢𝘳𝘺 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘧𝘰𝘳 𝘏𝘰𝘸𝘢𝘳𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘢𝘯𝘥 𝘯𝘦𝘪𝘨𝘩𝘣𝘰𝘳𝘪𝘯𝘨 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘪𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘪𝘰𝘯𝘴 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘊𝘩𝘪𝘭𝘥𝘳𝘦𝘯’𝘴 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭, 𝘎𝘦𝘰𝘳𝘨𝘦𝘵𝘰𝘸𝘯, 𝘜𝘚𝘋𝘈, 𝘝𝘈, 𝘢𝘯𝘥 𝘭𝘰𝘤𝘢𝘭 𝘣𝘪𝘰𝘵𝘦𝘤𝘩 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴. 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐈𝐧𝐬𝐭𝐚𝐥𝐥𝐢𝐧𝐠 𝐚 𝐍𝐞𝐰 𝐁𝐫𝐮𝐤𝐞𝐫 4.7𝐓 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐌𝐑 𝐈𝐦𝐚𝐠𝐢𝐧𝐠 𝐒𝐲𝐬𝐭𝐞𝐦. Bruker 4.7T preclinical MR imaging system was a gift from Children's National Hospital to Molecular Imaging Laboratory at Howard University. I worked closely with the Lab Director by providing many constructive feedbacks on budget evaluation, route of delivery, site planning, room organization, safety control, etc. I worked closely with the Engineer to slowly ramp the superconducting magnet and to carefully start up the system. I successfully implemented the CEST MRI method in the new scanner. 𝐌𝐞𝐧𝐭𝐨𝐫𝐢𝐧𝐠 𝐚𝐧𝐝 𝐓𝐞𝐚𝐜𝐡𝐢𝐧𝐠: I gained my mentoring and teaching experience when I worked at Howard University, UT Southwestern Medical Center, and UT Dallas. I lectured relevant courses at both undergraduate and graduate-level and mentored laboratory research for students (>10) of different levels from high school students to postdoctoral researchers. 𝐆𝐫𝐚𝐧𝐭 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧: I worked with Dr. Paul C. Wang to initiate a DOD instrument grant application. As a Co-PI of this application, I drafted the proposal with other researchers at Howard University. The application was submitted in August 2016, and was awarded in June 2017. This fund makes it possible for the Imaging Core to be equipped with a PET/CT scanner from Bruker, allowing for the Imaging Core to provide better service for Howard University and neighboring institutions. Show less 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘐𝘮𝘢𝘨𝘪𝘯𝘨 𝘓𝘢𝘣𝘰𝘳𝘢𝘵𝘰𝘳𝘺 𝘪𝘯 𝘏𝘰𝘸𝘢𝘳𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘪𝘴 𝘢 𝘴𝘺𝘯𝘦𝘳𝘨𝘪𝘴𝘵𝘪𝘤 𝘤𝘦𝘯𝘵𝘦𝘳 𝘧𝘰𝘳 𝘱𝘳𝘰𝘮𝘰𝘵𝘪𝘯𝘨 𝘮𝘶𝘭𝘵𝘪𝘥𝘪𝘴𝘤𝘪𝘱𝘭𝘪𝘯𝘢𝘳𝘺 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘧𝘰𝘳 𝘏𝘰𝘸𝘢𝘳𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘢𝘯𝘥 𝘯𝘦𝘪𝘨𝘩𝘣𝘰𝘳𝘪𝘯𝘨 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘪𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘪𝘰𝘯𝘴 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘊𝘩𝘪𝘭𝘥𝘳𝘦𝘯’𝘴 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭, 𝘎𝘦𝘰𝘳𝘨𝘦𝘵𝘰𝘸𝘯, 𝘜𝘚𝘋𝘈, 𝘝𝘈, 𝘢𝘯𝘥 𝘭𝘰𝘤𝘢𝘭 𝘣𝘪𝘰𝘵𝘦𝘤𝘩 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴… Show more 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘐𝘮𝘢𝘨𝘪𝘯𝘨 𝘓𝘢𝘣𝘰𝘳𝘢𝘵𝘰𝘳𝘺 𝘪𝘯 𝘏𝘰𝘸𝘢𝘳𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘪𝘴 𝘢 𝘴𝘺𝘯𝘦𝘳𝘨𝘪𝘴𝘵𝘪𝘤 𝘤𝘦𝘯𝘵𝘦𝘳 𝘧𝘰𝘳 𝘱𝘳𝘰𝘮𝘰𝘵𝘪𝘯𝘨 𝘮𝘶𝘭𝘵𝘪𝘥𝘪𝘴𝘤𝘪𝘱𝘭𝘪𝘯𝘢𝘳𝘺 𝘣𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘧𝘰𝘳 𝘏𝘰𝘸𝘢𝘳𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘢𝘯𝘥 𝘯𝘦𝘪𝘨𝘩𝘣𝘰𝘳𝘪𝘯𝘨 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘪𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘪𝘰𝘯𝘴 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘊𝘩𝘪𝘭𝘥𝘳𝘦𝘯’𝘴 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭, 𝘎𝘦𝘰𝘳𝘨𝘦𝘵𝘰𝘸𝘯, 𝘜𝘚𝘋𝘈, 𝘝𝘈, 𝘢𝘯𝘥 𝘭𝘰𝘤𝘢𝘭 𝘣𝘪𝘰𝘵𝘦𝘤𝘩 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴. 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐈𝐧𝐬𝐭𝐚𝐥𝐥𝐢𝐧𝐠 𝐚 𝐍𝐞𝐰 𝐁𝐫𝐮𝐤𝐞𝐫 4.7𝐓 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐌𝐑 𝐈𝐦𝐚𝐠𝐢𝐧𝐠 𝐒𝐲𝐬𝐭𝐞𝐦. Bruker 4.7T preclinical MR imaging system was a gift from Children's National Hospital to Molecular Imaging Laboratory at Howard University. I worked closely with the Lab Director by providing many constructive feedbacks on budget evaluation, route of delivery, site planning, room organization, safety control, etc. I worked closely with the Engineer to slowly ramp the superconducting magnet and to carefully start up the system. I successfully implemented the CEST MRI method in the new scanner. 𝐌𝐞𝐧𝐭𝐨𝐫𝐢𝐧𝐠 𝐚𝐧𝐝 𝐓𝐞𝐚𝐜𝐡𝐢𝐧𝐠: I gained my mentoring and teaching experience when I worked at Howard University, UT Southwestern Medical Center, and UT Dallas. I lectured relevant courses at both undergraduate and graduate-level and mentored laboratory research for students (>10) of different levels from high school students to postdoctoral researchers. 𝐆𝐫𝐚𝐧𝐭 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧: I worked with Dr. Paul C. Wang to initiate a DOD instrument grant application. As a Co-PI of this application, I drafted the proposal with other researchers at Howard University. The application was submitted in August 2016, and was awarded in June 2017. This fund makes it possible for the Imaging Core to be equipped with a PET/CT scanner from Bruker, allowing for the Imaging Core to provide better service for Howard University and neighboring institutions. Show less

Research Associate

• Sep 2007 - Oct 2010

𝘛𝘩𝘦 𝘚𝘩𝘦𝘳𝘳𝘺 𝘓𝘢𝘣 𝘪𝘯 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘛𝘦𝘹𝘢𝘴 𝘢𝘵 𝘋𝘢𝘭𝘭𝘢𝘴 𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘪𝘻𝘦𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘢𝘯𝘥 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘯𝘦𝘹𝘵-𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 “𝘴𝘮𝘢𝘳𝘵” 𝘔𝘙𝘐 𝘥𝘳𝘶𝘨𝘴 𝘵𝘩𝘢𝘵 𝘢𝘭𝘵𝘦𝘳 𝘵𝘩𝘦 𝘪𝘯𝘵𝘦𝘯𝘴𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘔𝘙𝘐 𝘴𝘪𝘨𝘯𝘢𝘭 𝘪𝘯 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘵𝘰 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘪𝘯𝘥𝘪𝘤𝘦𝘴 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘱𝘏 𝘢𝘯𝘥 𝘮𝘦𝘵𝘢𝘭 𝘪𝘰𝘯𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘪𝘯 𝘤𝘦𝘭𝘭𝘶𝘭𝘢𝘳 𝘮𝘦𝘵𝘢𝘣𝘰𝘭𝘪𝘴𝘮… Show more 𝘛𝘩𝘦 𝘚𝘩𝘦𝘳𝘳𝘺 𝘓𝘢𝘣 𝘪𝘯 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘛𝘦𝘹𝘢𝘴 𝘢𝘵 𝘋𝘢𝘭𝘭𝘢𝘴 𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘪𝘻𝘦𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘢𝘯𝘥 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘯𝘦𝘹𝘵-𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 “𝘴𝘮𝘢𝘳𝘵” 𝘔𝘙𝘐 𝘥𝘳𝘶𝘨𝘴 𝘵𝘩𝘢𝘵 𝘢𝘭𝘵𝘦𝘳 𝘵𝘩𝘦 𝘪𝘯𝘵𝘦𝘯𝘴𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘔𝘙𝘐 𝘴𝘪𝘨𝘯𝘢𝘭 𝘪𝘯 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘵𝘰 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘪𝘯𝘥𝘪𝘤𝘦𝘴 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘱𝘏 𝘢𝘯𝘥 𝘮𝘦𝘵𝘢𝘭 𝘪𝘰𝘯𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘪𝘯 𝘤𝘦𝘭𝘭𝘶𝘭𝘢𝘳 𝘮𝘦𝘵𝘢𝘣𝘰𝘭𝘪𝘴𝘮. 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Polymers have been extensively used as platforms for diagnostic and therapeutic purposes. Polymers used in drug development should have desirable pharmacokinetic, biodistribution, and less toxic properties. I prepared a polymer version of the MRI drug (J. Am. Chem. Soc. 2008, 130(42), 13854-13855.), which demonstrates very high detection sensitivity. No adverse effects were observed in the animals with an injection dose of 0.1 mmol/kg. To study the pharmacokinetics and biodistribution of the new polymer platform, the 64Cu-labeled polymer was synthesized. PET imaging results showed the new polymer displayed a very favorable pharmacokinetic property and biodistribution profile as it was quickly cleared through the kidneys with little accumulation in the liver, heart, and lungs. The biodistribution study results from isolated organs of mice at 2 hrs post-injection were consistent with the results obtained from PET imaging. Preclinical results indicate that the new polymer is a desirable platform suitable for diagnostic and therapeutic applications. Show less 𝘛𝘩𝘦 𝘚𝘩𝘦𝘳𝘳𝘺 𝘓𝘢𝘣 𝘪𝘯 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘛𝘦𝘹𝘢𝘴 𝘢𝘵 𝘋𝘢𝘭𝘭𝘢𝘴 𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘪𝘻𝘦𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘢𝘯𝘥 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘯𝘦𝘹𝘵-𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 “𝘴𝘮𝘢𝘳𝘵” 𝘔𝘙𝘐 𝘥𝘳𝘶𝘨𝘴 𝘵𝘩𝘢𝘵 𝘢𝘭𝘵𝘦𝘳 𝘵𝘩𝘦 𝘪𝘯𝘵𝘦𝘯𝘴𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘔𝘙𝘐 𝘴𝘪𝘨𝘯𝘢𝘭 𝘪𝘯 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘵𝘰 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘪𝘯𝘥𝘪𝘤𝘦𝘴 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘱𝘏 𝘢𝘯𝘥 𝘮𝘦𝘵𝘢𝘭 𝘪𝘰𝘯𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘪𝘯 𝘤𝘦𝘭𝘭𝘶𝘭𝘢𝘳 𝘮𝘦𝘵𝘢𝘣𝘰𝘭𝘪𝘴𝘮… Show more 𝘛𝘩𝘦 𝘚𝘩𝘦𝘳𝘳𝘺 𝘓𝘢𝘣 𝘪𝘯 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘛𝘦𝘹𝘢𝘴 𝘢𝘵 𝘋𝘢𝘭𝘭𝘢𝘴 𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘪𝘻𝘦𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘢𝘯𝘥 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘯𝘦𝘹𝘵-𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 “𝘴𝘮𝘢𝘳𝘵” 𝘔𝘙𝘐 𝘥𝘳𝘶𝘨𝘴 𝘵𝘩𝘢𝘵 𝘢𝘭𝘵𝘦𝘳 𝘵𝘩𝘦 𝘪𝘯𝘵𝘦𝘯𝘴𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘔𝘙𝘐 𝘴𝘪𝘨𝘯𝘢𝘭 𝘪𝘯 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘵𝘰 𝘣𝘪𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘪𝘯𝘥𝘪𝘤𝘦𝘴 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘱𝘏 𝘢𝘯𝘥 𝘮𝘦𝘵𝘢𝘭 𝘪𝘰𝘯𝘴 𝘪𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘵 𝘪𝘯 𝘤𝘦𝘭𝘭𝘶𝘭𝘢𝘳 𝘮𝘦𝘵𝘢𝘣𝘰𝘭𝘪𝘴𝘮. 𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Polymers have been extensively used as platforms for diagnostic and therapeutic purposes. Polymers used in drug development should have desirable pharmacokinetic, biodistribution, and less toxic properties. I prepared a polymer version of the MRI drug (J. Am. Chem. Soc. 2008, 130(42), 13854-13855.), which demonstrates very high detection sensitivity. No adverse effects were observed in the animals with an injection dose of 0.1 mmol/kg. To study the pharmacokinetics and biodistribution of the new polymer platform, the 64Cu-labeled polymer was synthesized. PET imaging results showed the new polymer displayed a very favorable pharmacokinetic property and biodistribution profile as it was quickly cleared through the kidneys with little accumulation in the liver, heart, and lungs. The biodistribution study results from isolated organs of mice at 2 hrs post-injection were consistent with the results obtained from PET imaging. Preclinical results indicate that the new polymer is a desirable platform suitable for diagnostic and therapeutic applications. Show less